Late-midlife lifestyle and brain and cognitive changes in individuals on the AD versus non-AD continuum.

IF 4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2025-04-15 eCollection Date: 2025-04-01 DOI:10.1002/dad2.70101

Julie E Oomens, Karly A Cody, Lianlian Du, Erin M Jonaitis, Rachel L Studer, Nathaniel A Chin, Sebastian Köhler, Pieter Jelle Visser, Stephanie J B Vos, Rebecca E Langhough, Willemijn J Jansen, Sterling C Johnson

{"title":"Late-midlife lifestyle and brain and cognitive changes in individuals on the AD versus non-AD continuum.","authors":"Julie E Oomens, Karly A Cody, Lianlian Du, Erin M Jonaitis, Rachel L Studer, Nathaniel A Chin, Sebastian Köhler, Pieter Jelle Visser, Stephanie J B Vos, Rebecca E Langhough, Willemijn J Jansen, Sterling C Johnson","doi":"10.1002/dad2.70101","DOIUrl":null,"url":null,"abstract":"Introduction: We investigated whether a composite measure of late-midlife lifestyle was associated with (1) longitudinal brain changes and (2) cognitive changes when adjusting for these brain changes.Methods: We used linear mixed models to examine whether the LIfestyle for BRAin Health (LIBRA) index was associated with changes in tau, white matter hyperintensity, neurodegeneration, and cognition and whether changes were similar in amyloid positive (A+; > 17 Centiloids) and negative participants.Results: We included 324 individuals from the Wisconsin Registry for Alzheimer's Prevention (39% apolipoprotein E [APOE] <math><mrow><mi>ε</mi></mrow> </math> 4 carrier, 30% A+, prior baseline age 67 [50-75]). The LIBRA index was not associated with biomarker trajectories or the primary cognitive composite outcome trajectory. There were inconsistent effects on secondary domain-specific cognitive trajectories. In contrast, tau and neurodegeneration were strongly associated with cognitive trajectories.Discussion: In the age-range and disease-range studied, lifestyle did not exhibit a meaningful effect on Alzheimer's disease or vascular biomarker accumulation and was not consistently associated with cognitive trajectories.Highlights: In this age-range, the LIfestyle for BRAin Health (LIBRA) index was not associated with biomarker trajectories.The LIBRA index was not consistently associated with cognitive trajectories.Effects of lifestyle, if any, may take more time to manifest.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 2","pages":"e70101"},"PeriodicalIF":4.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000247/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: We investigated whether a composite measure of late-midlife lifestyle was associated with (1) longitudinal brain changes and (2) cognitive changes when adjusting for these brain changes.

Methods: We used linear mixed models to examine whether the LIfestyle for BRAin Health (LIBRA) index was associated with changes in tau, white matter hyperintensity, neurodegeneration, and cognition and whether changes were similar in amyloid positive (A+; > 17 Centiloids) and negative participants.

Results: We included 324 individuals from the Wisconsin Registry for Alzheimer's Prevention (39% apolipoprotein E [APOE] $ε$ 4 carrier, 30% A+, prior baseline age 67 [50-75]). The LIBRA index was not associated with biomarker trajectories or the primary cognitive composite outcome trajectory. There were inconsistent effects on secondary domain-specific cognitive trajectories. In contrast, tau and neurodegeneration were strongly associated with cognitive trajectories.

Discussion: In the age-range and disease-range studied, lifestyle did not exhibit a meaningful effect on Alzheimer's disease or vascular biomarker accumulation and was not consistently associated with cognitive trajectories.

Highlights: In this age-range, the LIfestyle for BRAin Health (LIBRA) index was not associated with biomarker trajectories.The LIBRA index was not consistently associated with cognitive trajectories.Effects of lifestyle, if any, may take more time to manifest.

查看原文本刊更多论文

阿尔茨海默病患者与非阿尔茨海默病患者的中老年生活方式与大脑和认知变化。

前言：我们研究了中年生活方式的综合测量是否与(1)纵向大脑变化和(2)调整这些大脑变化时的认知变化有关。方法：我们使用线性混合模型来检验LIBRA （LIfestyle for BRAin Health）指数是否与tau、白质高密度、神经变性和认知的变化相关，以及淀粉样蛋白阳性(A+；bbb17个Centiloids)和阴性参与者。结果：我们纳入了来自威斯康星州阿尔茨海默病预防登记处的324名个体（39%载脂蛋白E [APOE] ε 4携带者，30% A+，先前基线年龄67[50-75]）。LIBRA指数与生物标志物轨迹或主要认知复合结局轨迹无关。对次级领域特定认知轨迹的影响不一致。相反，tau蛋白和神经退行性变与认知轨迹密切相关。讨论：在研究的年龄范围和疾病范围中，生活方式对阿尔茨海默病或血管生物标志物积累没有表现出有意义的影响，并且与认知轨迹并不一致。重点：在这个年龄范围内，大脑健康生活方式（LIBRA）指数与生物标志物轨迹无关。LIBRA指数并不总是与认知轨迹相关。生活方式的影响，如果有的话，可能需要更多的时间来显现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.